CXCR2 and chronic obstructive pulmonary disease: COPD patients treated with selective CXCR2 receptor antagonists, Navarixin or Danirixin, presented a significant improvement in FEV1 compared to placebo group and suggested a clinically important anti-inflammatory effect of the CXCR2 antagonism (60).